George Blanck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7977592/publications.pdf

Version: 2024-02-01

97	1,928	394286	302012
papers	citations	19 h-index	39 g-index

98	98	98	1113
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature, 1990, 348, 744-747.	13.7	671
2	Detection of Productively Rearranged TcR-Î± Vâ€“J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Informatics, 2016, 15, CIN.S35784.	0.9	46
3	Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) Type IV promoter by interferon regulatory factors 1 and 2. Oncogene, 1999, 18, 5889-5903.	2.6	45
4	Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. Journal of Neuro-Oncology, 2018, 140, 697-704.	1.4	41
5	Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Human Vaccines and Immunotherapeutics, 2017, 13, 501-506.	1.4	40
6	Histone Deacetylase Activity Represses Gamma Interferon-Inducible HLA-DR Gene Expression following the Establishment of a DNase I-Hypersensitive Chromatin Conformation. Molecular and Cellular Biology, 2001, 21, 6495-6506.	1.1	39
7	Substantially reduced expression of PIAS1 is associated with colon cancer development. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1287-1291.	1.2	38
8	Elucidating feedâ€‘forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome. Oncology Letters, 2018, 16, 2757-2763.	0.8	32
9	T-cell receptor-Î± CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 615-623.	1.2	32
10	Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene, 2020, 39, 1773-1783.	2.6	29
11	Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-Î±/Î² V(D)J recombinations correlates with PD-1 expression. International Journal of Cancer, 2017, 140, 2568-2576.	2.3	25
12	Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cellular and Molecular Immunology, 2020, 17, 776-778.	4.8	25
13	The ADC API: A Web API for the Programmatic Query of the AIRR Data Commons. Frontiers in Big Data, 2020, 3, 22.	1.8	24
14	A scoring system for the electrostatic complementarities of Tâ€cell receptors and cancerâ€mutant amino acids: multiâ€cancer analyses of associated survival rates. Immunology, 2020, 159, 373-383.	2.0	23
15	IFN-Î³ inducibility of class II transactivator is specifically lacking in human tumour lines: Relevance to retinoblastoma protein rescue of IFN-Î³ inducibility of the HLA class II genes. Immunology and Cell Biology, 1997, 75, 325-332.	1.0	22
16	T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-Î² VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunology, Immunotherapy, 2017, 66, 403-410.	2.0	22
17	High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer. Molecular Immunology, 2021, 135, 247-253.	1.0	22
18	Oct-1 Maintains an Intermediate, Stable State of HLA-DRA Promoter Repression in Rb-defective Cells. Journal of Biological Chemistry, 2004, 279, 28911-28919.	1.6	21

#	Article	IF	Citations
19	An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: Towards a model of the cancer cell/B-cell microenvironment. Experimental and Molecular Pathology, 2014, 97, 585-589.	0.9	21
20	T-cell receptor-Î² V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunology, Immunotherapy, 2018, 67, 885-892.	2.0	21
21	MAPT (Tau) expression is a biomarker for an increased rate of survival for lowâ€'grade glioma. Oncology Reports, 2019, 41, 1359-1366.	1.2	21
22	Functionally distinct gene classes as bigger or smaller transcription factor traps: A possible stochastic component to sequential gene expression programs in cancer. Gene, 2014, 536, 398-406.	1.0	20
23	Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene, 2001, 20, 4219-4227.	2.6	19
24	High Level Class IItrans-Activator Induction Does Not Occur with Transient Activation of the IFN-Î³ Signaling Pathway. Journal of Immunology, 2001, 166, 1041-1048.	0.4	19
25	Big genes are big mutagen targets: A connection to cancerous, spherical cells?. Cancer Letters, 2015, 356, 479-482.	3.2	19
26	MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle, 2018, 17, 2474-2483.	1.3	19
27	Copy number loss or silencing of apoptosis-effector genes in cancer. Gene, 2015, 554, 50-57.	1.0	18
28	Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-Î³/Î´ Recombinations. Cancer Microenvironment, 2018, 11, 41-49.	3.1	18
29	TcR-Î± recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers. International Immunology, 2018, 30, 35-40.	1.8	18
30	Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research and Treatment, 2019, 173, 167-177.	1.1	18
31	A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma. International Journal of Immunogenetics, 2021, 48, 409-418.	0.8	18
32	Interferon regulatory factor-2 point mutations in human pancreatic tumors. International Journal of Cancer, 2000, 87, 803-808.	2.3	17
33	Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. Cancer Microenvironment, 2018, 11, 51-59.	3.1	17
34	T cell receptor-Î² J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. Immunologic Research, 2018, 66, 219-223.	1.3	16
35	T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Human Immunology, 2019, 80, 237-242.	1.2	16
36	Genes that contribute to cancer fusion genes are large and evolutionarily conserved. Cancer Genetics and Cytogenetics, 2009, 191, 78-84.	1.0	15

#	Article	IF	Citations
37	Size Matters: Sequential Mutations in Tumorigenesis May Reflect the Stochastic Effect of Mutagen Target Sizes. Genes and Cancer, 2011, 2, 927-931.	0.6	15
38	Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. Laboratory Investigation, 2017, 97, 1516-1520.	1.7	15
39	Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Translational Oncology, 2021, 14, 101069.	1.7	15
40	Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Human Vaccines and Immunotherapeutics, 2013, 9, 784-789.	1.4	13
41	Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?. Human Vaccines and Immunotherapeutics, 2016, 12, 120-123.	1.4	13
42	Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. Breast Cancer Research and Treatment, 2021, 185, 591-600.	1.1	13
43	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Research, 2022, 82, 929-942.	0.4	13
44	RB and A novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-Î³ induction of the class II transactivator ciita in class II non-inducible RB-defective tumor lines. International Journal of Cancer, 1995, 62, 461-465.	2.3	12
45	TRBâ€‘1 usage, in combination with the HLAâ€A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. International Journal of Immunogenetics, 2019, 46, 31-37.	0.8	12
46	Immunogenomics Parameters for Patient Stratification in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 88, 619-629.	1.2	12
47	Anticipating designer drug-resistant cancer cells. Drug Discovery Today, 2015, 20, 790-793.	3.2	11
48	Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. Cell and Tissue Research, 2016, 363, 491-496.	1.5	11
49	Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene, 2017, 614, 37-48.	1.0	11
50	Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. International Journal of Cancer, 2018, 142, 988-998.	2.3	11
51	Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunology, Immunotherapy, 2004, 53, 1-16.	2.0	10
52	Smoking correlates with increased cytoskeletal proteinâ€‐related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. Physiological Reports, 2016, 4, e13045.	0.7	10
53	Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochemical and Biophysical Research Communications, 2018, 503, 2218-2225.	1.0	9
54	Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas. Pediatric Hematology and Oncology, 2021, 38, 251-264.	0.3	9

#	Article	IF	Citations
55	A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics and Proteomics, 2015, 12, 283-90.	1.0	9
56	Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments. Journal of Biomolecular Structure and Dynamics, 2023, 41, 4632-4640.	2.0	9
57	Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle, 2015, 14, 2494-2500.	1.3	8
58	Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 18-23.	3.3	8
59	Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells. Journal of Molecular Neuroscience, 2021, 71, 2393-2404.	1.1	8
60	Components of the IFN-gamma signaling pathway in tumorigenesis. Archivum Immunologiae Et Therapiae Experimentalis, 2002, 50, 151-8.	1.0	8
61	Combined IL-8 and TGF-Î² blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunology Letters, 2009, 122, 26-29.	1.1	7
62	Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach. Cell Cycle, 2016, 15, 1572-1578.	1.3	7
63	MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Molecular and Clinical Oncology, 2017, 7, 1119-1121.	0.4	7
64	Matrixâ€Metalloprotease Resistant Mucinâ€16 (MUC16) Peptide Mutants Represent a Worse Lung Adenocarcinoma Outcome. Proteomics - Clinical Applications, 2019, 13, e1800155.	0.8	7
65	CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Anticancer Research, 2005, 25, 3889-92.	0.5	7
66	TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. Cell Cycle, 2016, 15, 2157-2163.	1.3	6
67	Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 459-468.	1.2	6
68	Specific TCR Vâ€“J gene segment recombinations leading to the identification pan-Vâ€“J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1314-1322.	0.6	6
69	Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Molecular Immunology, 2009, 46, 569-575.	1.0	5
70	Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer. Biomedical Reports, 2017, 7, 163-168.	0.9	5
71	The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell International, 2017, 17, 121.	1.8	5
72	Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation, 2019, 99, 1287-1295.	1.7	5

#	Article	IF	Citations
73	An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell International, 2019, 19, 73.	1.8	5
74	MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. Clinical Biochemistry, 2019, 63, 85-91.	0.8	5
75	Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology, 2020, 33, 404-412.	0.6	5
76	B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate. Anticancer Research, 2020, 40, 2043-2051.	0.5	5
77	Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates. Leukemia and Lymphoma, 2021, 62, 1711-1720.	0.6	5
78	Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: Cancer cell expression of HLA-DR. Gene, 2013, 512, 403-407.	1.0	4
79	Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment and Research Communications, 2020, 24, 100196.	0.7	4
80	TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Human Immunology, 2020, 81, 692-696.	1.2	4
81	Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome. Current Genomics, 2017, 18, 287-297.	0.7	4
82	Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Research, 2015, 35, 25-9.	0.5	4
83	Unifying the genomics-based classes of cancer fusion gene partners: large cancer fusion genes are evolutionarily conserved. Cancer Genomics and Proteomics, 2012, 9, 389-95.	1.0	3
84	CNV assessments associated with outcome distinctions for adult and pediatric cancers: Loss of BRCA1 in neuroblastoma associates with a lower survival probability. Gene, 2022, 836, 146673.	1.0	3
85	A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. Anticancer Research, 2006, 26, 1733-8.	0.5	2
86	The Rise of the Biomedical Sciences Master's Program at U.S. Medical Colleges. Teaching and Learning in Medicine, 2014, 26, 409-411.	1.3	1
87	The future of cancer research. Human Vaccines and Immunotherapeutics, 2014, 10, 700-702.	1.4	1
88	Overlap of the cancer genome atlas and the immune epitope database. Oncology Letters, 2016, 12, 2982-2984.	0.8	1
89	HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Human Vaccines and Immunotherapeutics, 2016, 12, 593-598.	1.4	1
90	De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions. Biomedical Reports, 2017, 6, 211-216.	0.9	1

#	Article	IF	Citations
91	High-level intrinsic disorder explains the universality of CLIP binding to diverse MHC class II variants. Cellular and Molecular Immunology, 2018, 15, 76-78.	4.8	1
92	Germline cytoskeletal and extra-cellular matrix-related single nucleotide variations associated with distinct cancer survival rates. Gene, 2018, 669, 91-98.	1.0	1
93	TRAV gene segments further away from the TRAJ gene segment cluster appear more commonly in human tumor and blood samples. Molecular Immunology, 2019, 116, 174-179.	1.0	1
94	Letter to the Editor: Giant proteins and cancer chemotherapy cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H718-H718.	1.5	1
95	QUANTITATIVE MORPHOLOGICAL AND MOLECULAR PATHOLOGY OF THE HUMAN THYMUS CORRELATE WITH INFANT CAUSE OF DEATH. Technology and Innovation, 2014, 16, 55-62.	0.2	0
96	Exploiting adaptive immune receptor recombination read recoveries from exome files to identify subsets of <scp>ALL</scp> and to establish <scp>TCR</scp> features that correlate with better outcomes. International Journal of Laboratory Hematology, 2022, , .	0.7	0
97	Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A panâ€'cancer analysis. Biomedical Reports, 2022, 17, .	0.9	0